Idoko O T, Roberts E, Cox M, Jafali J, Njie-Jobe J, Mackenzie G, Ota M O, Kampmann B
Medical Research Council Unit, The Gambia.
Medical Research Council Unit, The Gambia.
Vaccine. 2014 Aug 6;32(36):4620-4. doi: 10.1016/j.vaccine.2014.06.078. Epub 2014 Jun 25.
Following a landmark clinical trial, the vaccine against Haemophilus influenzae type b (Hib) was introduced in The Gambia in 1997. Whilst the immunogenicity of this vaccine is well established subsequent to the doses administered under the EPI schedule, little data exists assessing longevity of protection, using serology. Such data are needed however to predict the susceptibility to Hib at the population level. To determine antibody persistence in 5-6 year old fully vaccinated Gambian children compared with older children, adolescents and young adults, 427 serum samples from healthy 5-37 year old participants were tested for Hib antibodies using VaccZyme Human Anti-Hib ELISA kits. 86% of the children who had received 3 doses of Hib vaccine in infancy had Hib antibody concentrations ≥0.15 mg/l at the age of 5-6 years. This proportion was 76% for adolescents who had also largely been vaccinated and 90% for adults who had never received Hib vaccine. Although most participants had anti-Hib antibody above concentrations putatively defined as protective, significantly fewer had concentrations thought to confer long-term protection. This suggests a population with insufficient or waning antibody that may be susceptible to breakthrough disease and transmission.
在一项具有里程碑意义的临床试验之后，1997年在冈比亚引入了b型流感嗜血杆菌（Hib）疫苗。虽然在扩大免疫规划（EPI）计划下接种该疫苗后的免疫原性已得到充分证实，但使用血清学评估保护持久性的数据却很少。然而，需要此类数据来预测人群对Hib的易感性。为了确定5至6岁完全接种疫苗的冈比亚儿童与年龄较大的儿童、青少年和年轻人相比的抗体持久性，使用VaccZyme Human Anti-Hib ELISA试剂盒对427名5至37岁健康参与者的血清样本进行了Hib抗体检测。在婴儿期接受过3剂Hib疫苗接种的儿童中，86%在5至6岁时Hib抗体浓度≥0.15 mg/l。在也大多接种过疫苗的青少年中这一比例为76%，在从未接种过Hib疫苗的成年人中为90%。尽管大多数参与者的抗Hib抗体浓度高于假定定义的保护浓度，但被认为能提供长期保护的浓度的参与者明显较少。这表明该人群抗体不足或正在减少，可能易患突破性疾病和传播。
